chevron_leftBack
As of 24 April 2025, STCube, Inc. has a market cap of $302.68M USD, ranking #14874 globally and #451 in South Korea. It ranks #2108 in the Technology sector, and #40 in the Electronics & Computer Distribution industry.
Key Stats
Market Cap
$302.68MUSD
432.06B KRW
Enterprise Value
$246.95MUSD
352.51B KRW
Revenue (TTM)
$7.91MUSD
11.3B KRW
EBITDA (TTM)
-$14.99MUSD
-21.4B KRW
Net Income (TTM)
-$15.02MUSD
-21.44B KRW
EBITDA Margin
-189%
Profit Margin
-190%
Company Profile
Country (HQ)
Sector
Technology
Industry
Electronics & Computer Distribution
CEO
Hyunjin Jung
open_in_new
Employees
17
Founded
1989
Website
stcube.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 4.3% | 6% | -7.3% | -32% | -2.9% | 31% |
Upcoming Earnings
Earnings Date
Wed, May 14
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
052020
(주)에스티큐브
ISIN: KR7052020005
Shares Out.:
Shares Outstanding:
67.933M1
Shares Float:
65.448M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
6.36K KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About STCube, Inc.
STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pipeline consists of various anti-cancer drugs, including anti PD-L1 Ab and anti PD-1 Ab in preclinical study, and anti STT-005 for solid tumor; anti STT-003 Ab in phase-1 for lung, head, and neck cancer; small molecule STT-011 inhibitor candidate development for pancreatic cancer; anti STT-012 Ab for breast and prostate cancer; and anti STT-013 Ab for solid tumor. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008. The company was founded in 1989 and is headquartered in Seoul, South Korea.
